trending Market Intelligence /marketintelligence/en/news-insights/trending/rxy6br4zik5i9tth9dyfoa2 content esgSubNav
In This List

Scythian nears CannCure deal closing with equity transfer in Fla.-based clinic

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Scythian nears CannCure deal closing with equity transfer in Fla.-based clinic

Scythian Biosciences Corp. said its acquisition target CannCure Investments Inc. received clearance from Florida's Department of Health to buy a 60% stake in 3 Boys Farms LLC.

Toronto-based Scythian has agreed to acquire a 70% stake in CannCure, with an option to buy the remaining 30% equity within 15 months after the deal closes.

The deal closing was subject to CannCure's acquisition of two Florida-based organizations, including 3 Boys Farms, a licensed medical marijuana treatment center.

Florida's Department of Health's office of medical marijuana also approved the transfer of 3 Boys' license to operate as a medical marijuana treatment center in the state.

The transfer of the remaining 40% stake to CannCure will close shortly after getting all required governmental approvals from the Department of Health.

Scythian Biosciences, a Canadian medical cannabis company, has previously stated that it expects to close CannCure deal on or around Oct. 15.